drugset / Trial / NCT01797081

BOTOX® in the Treatment of Crow's Feet Lines in Japan

NCT01797081 ↗

Phase 3 Completed 300 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).

Timeline

Start
2013-01-31
Primary completion
2013-07-18
Completion
2014-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 12 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 24 iu Other

Indications